(3 years, 7 months ago)
Commons ChamberThese decisions are based on the evidence, and the Joint Biosecurity Centre puts forward the evidence for red-listing. In the first instance, the red list is there to stop new variants, but this variant was not a known variant under investigation. Because of the increase in the overall rates—the overall positivity—of people coming to this country, first from Pakistan and Bangladesh at the start of April, and then towards the end of April from India, we took the precautionary decision to put them on the red list. That is a matter of fact; I am happy to state that. The job now is to make sure we keep this all under control.
The success of the vaccination programme has surpassed expectations, in part because of the very effective work that was done in tackling vaccine hesitancy at the start, but it is implicit in my right hon. Friend’s statement that, in Bolton and Blackburn particularly, there has been less success with persuading some people. What does he consider to be the model of good practice in persuading hard-to-reach groups? Where does he think that has taken place, and how will he roll it out in other areas?
I am incredibly proud that the UK has the highest measured rate of enthusiasm for taking the vaccine in the world, and especially that such a diverse nation has been able to achieve that record by taking this positive attitude and having people from Her Majesty down setting out the value of being vaccinated. I pay tribute to the comms team at NHS England and my communications team from across Whitehall, which have taken the lessons for how to get a positive narrative, especially on social media, and made sure we fought lies with objective truth. That has been fantastic.
On the ground, there are some really good examples. I mentioned my visit to Brent central mosque and I pay tribute to the people there. Some brilliant work has happened in Leicester; for instance, there was a vaccination centre right next to an area heavily populated by those of Somali background, but they were not going to the vaccination centre despite the fact that it was next door and so we set up a vaccination centre almost next door but where the doctors and clinicians are themselves Somalis. We then we saw a very sharp rate in the Somali vaccination rate. That is one example that I can immediately add to the elucidation of the answer to this question, but there are legion. People from around the world have been coming, via Zoom, to talk to some of our more innovative vaccination centres, be it at the mosque, at the Hindu temple in Neasden, which is doing brilliant work, in Leicester or, now, in Bolton and Blackburn, where I hope we can make some really significant progress. Frankly, this country should be proud of how people have pulled together to make this vaccination programme work.
(3 years, 10 months ago)
Commons ChamberYes, that is exactly the principle on which we are proceeding. I pay tribute to the work that the hon. Lady does in this area and in always speaking up for those who are in in-patient care. It is very important that we make sure that there is equal and fair support for all according to clinical need, and that will be addressed in the next phase of the roll-out, once we have ensured that the offer to all those in categories 1 to 4 is achieved by next Monday.
I put on record my thanks to everybody working at Newbury racecourse for leading a fantastic vaccination programme for my constituency. I welcome my right hon. Friend’s statement about very high rates of take-up of the vaccine. What has the take-up rate been among those under the age of 70 who have been offered it so far? What conversations has he had with the vaccine Minister about dispelling one of the most persistent myths that has been raised with me by young women—that the vaccine could negatively affect their fertility?
There is no evidence at all that the vaccine negatively affects fertility. There are many myths about vaccines, and I am very glad that they have largely been rightly ignored by the British public when they are inaccurate. The way we try to tackle such myths is by putting out as much positive, accurate, objective information from objective sources as possible, both on the NHS website and through the chief medical officer and deputy chief medical officers answering questions whenever possible. I am glad that my hon. Friend has raised that issue. I will ask one of the deputy chief medical officers to write to her, and we will publish that letter to provide the further reassurance that she asks for.
(4 years ago)
Commons ChamberMy hon. Friend knows from personal experience what this disease can be like. He has been a powerful voice for Ashfield, and I will take his representations into account when we make a decision on Wednesday.
It is extremely concerning that more than 1,000 cases of the new variant have been identified in the south-east, but I understand that the vaccine still works. Data published by the ONS today shows that the mortality rate will fall by 84% when all over-70s are vaccinated. Could my right hon. Friend tell the House when he thinks that will be and what it will mean for the tiering system?
Believe me, I would love to be able to answer that question. We do not know, because it depends on the speed of manufacture of the vaccines and the approval or not of the Oxford vaccine by the MHRA. But the essence of the way that my hon. Friend asks the question is exactly how we are thinking about it in Government.
(4 years, 3 months ago)
Commons ChamberWe have strong protocols on the return to school. I am really glad about the success of the policy to get all schools back; it is one of the Government’s unsung successes over recent weeks, and is working effectively. The guidelines set out very clearly when testing is appropriate. Testing is appropriate for people who have symptoms. Close contacts of people who have symptoms need to self-isolate and not get a test unless they have symptoms because getting a test would not allow them to leave self-isolation anyway because of the risk of false negatives. That is why the policy is as it is. We have given each school 10 or more tests so that they can easily use them in an emergency, and that has been warmly welcomed by most schools.
A successful return to school in west Berkshire has been matched with a reduction in the availability of testing. I have listened to my right hon. Friend this morning; if there is a reluctance to impose more stringent eligibility criteria, would he consider an order of priority based on, for example, working parents and teachers being able to access tests sooner?
Again, there has not been a reduction in capacity in Berkshire or anywhere else in the country. There has been an increase in capacity. My hon. Friend makes a good point, though, about prioritisation. The question is how to enforce prioritisation without putting in place barriers that slow down access to tests for people who need them. We are looking at that now.
(4 years, 4 months ago)
Commons ChamberThose projections did not take into account the actions that the UK Government are undertaking.
I welcome the news today about the successful trial of the Oxford vaccine. The question on my constituents’ lips is: when will that be available on the market? I know my right hon. Friend cannot give those assurances, but could he assist my constituents first by saying when the trial is due to end, and secondly by giving assurances that the route to market for a successful vaccine will be as quick as that for dexamethasone?
On the first point, I am afraid that I cannot give my hon. Friend the clarity that she understandably seeks on behalf of her constituents, because it is a scientific question. As the rate of new infections has fallen, so the clinical trials have had to be a bit longer, because they are trying to prove a negative: that if someone has had the vaccine, they do not then get the disease. As a result, AstraZeneca has taken the vaccine around the world and put trials in countries where there is a much higher rate of infection. The rule with clinical trials is that, as soon as a trial comes to a conclusion that is beyond reasonable scientific doubt, the results are brought forward immediately. It is not a trial with a specific end date; it is a trial that runs until it is concluded scientifically, one way or the other. I hope that explanation—well, it is not as good as a date, but I hope that people accept it.
On the second point, my hon. Friend is absolutely right. We have been working hand in glove with these brilliant scientists, and we should put it on the record, even though it might take me an extra 30 seconds to say it, Mr Deputy Speaker, that the Medicines and Healthcare Products Regulatory Agency has done an amazing job. Alongside the scientists, it has made sure the trials are designed so that it can approve the results as soon as the results come forward—essentially, in parallel, rather than afterward, which is the norm. The MHRA has played a blinder; it is one of the reasons that the UK is at the forefront in vaccines and treatments. That means the vaccine will be available as soon as humanly possible as soon as the science is proven.
(4 years, 5 months ago)
Commons ChamberOf course it has been necessary to have tight controls over visitors in hospitals during this crisis, because people picking up nosocomial infections in hospital has been one part of the epidemic that we need to get under control. My heart goes out to those many people who have made sacrifices, including the hon. Member’s constituent, and of course we always keep this under review.
My hon. Friend makes an important point. She may have seen this morning that in Germany, North Rhine-Westphalia has been put back into lockdown because of a local outbreak. So far, the local outbreaks we have seen have essentially been clusters in very small areas, and we have been able to bust those clusters and tackle them. We do, of course, hold the powers to have wider local lockdowns. Those will be based on judgments based on the epidemiological advice and advised by the joint biosecurity centre, working with all the relevant agencies.
(4 years, 6 months ago)
Commons ChamberI would like to begin by congratulating my right hon. Friend on the successful roll-out of dexamethasone, but my question is about international comparison. We were one of the later countries to be hit by the virus. There are others who have begun the process of moving out of lockdown ahead of us. What countries does my right hon. Friend see as the paradigm for the United Kingdom, and what steps, if any, are we taking to share information with healthcare professionals to emulate best practice?
This is a great question, and we look all the time for countries around the world that we can learn from. It is true that, in terms of where we were on the epidemiological curve, we went into lockdown before many European countries—before Germany, Spain and Italy—with lower cases per million. But we still learned from them. For instance, one of the lessons from Germany is that a massive testing regime is incredibly important, and we now have a much bigger testing regime than Germany, which is terrific, and we have built that up. We also look to the far east, with its lessons from severe acute respiratory syndrome and middle east respiratory syndrome, which it learned more directly. It has the contact tracing which we are putting in place. We are constantly learning. Probably the single most important thing that we can do in this crisis is constantly look around the world for places where we can learn best practice, and then implement it here.
(4 years, 7 months ago)
Commons ChamberUrgent Questions are proposed each morning by backbench MPs, and up to two may be selected each day by the Speaker. Chosen Urgent Questions are announced 30 minutes before Parliament sits each day.
Each Urgent Question requires a Government Minister to give a response on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
The more people who download the app the better it will be and the more effective it will be in keeping people safe. However, even small numbers downloading it will help us to spot hotspots and so will bring some value. I was really delighted yesterday afternoon to hear from Isle of Wight Radio, which stated that 80% of people on the Isle of Wight in an early survey said that they wanted to download the app. That would be a terrific result. I pay tribute to the work of Isle of Wight Radio and the local press on the Isle of Wight, who have taken to Isle of Wight’s important role in piloting this roll-out with enthusiasm. There is no numerical answer to the hon. Gentleman’s question. The answer is that as many as possible will make us as safe as possible.
I welcome the launch of the test, track and trace app, but one of the apparent challenges is that those who could benefit from it the most, namely the elderly, may be those who are least likely to be able to access it because they do not have a smart phone. What assessment has my right hon. Friend made of the probable lower take-up by that honourable cohort?
We have looked into this very important question. Of course, test, track and trace is a system. The app is one part of it, but the human contact traces are an important part of the system, as is the advice we give to people to contact their own significant contacts themselves. The whole system has been designed knowing that a proportion of the population does not have a smart phone. There are many older people who do have smart phones. I am sure, for instance, that the shadow Secretary of State is probably sending a message to his parents right now on the smart phone he is using instead of listening to my hon. Friend’s question. There is a serious point, which is that of course we have had to take that into account. It is another reason why the Isle of Wight is such a good place to trial it, because there are elderly residents on the Isle of Wight. We will work out and learn a lot from how effective that trial is.
(4 years, 10 months ago)
Commons ChamberWith your permission, Mr Speaker, I will answer Questions 1, 4, 6, 11 and 20 together. [Interruption.] General practice is a popular subject.
We will create an extra 50 million appointments a year in primary care so that everyone can go to the GP when they need to.
Yes. My hon. Friend has already become an incredibly strong voice for Wolverhampton, and it was a pleasure to visit Tettenhall medical practice, which has joined with other GP practices to form a primary care network, which I hope will strengthen its resilience and enable it to provide extended access to appointments, which is what he is campaigning for. I am pleased, too, with the extra 16,000 appointments in Wolverhampton in the last quarter. As this shows, we are driving up the number of appointments, but we also appreciate, understand and feel the frustration people feel when they cannot get decent access to GP appointments.
Changes to pension contributions mean that some senior GPs, including in Newbury, are being hit with extra tax charges if they work overtime, which is leading to the paradoxical situation of GPs paying to work and so reducing their hours or taking early retirement. What steps is the Secretary of State’s Department taking to address this situation?
Tax is, of course, a matter for the Treasury, and the Chancellor would not be thrilled if I announced tax policy in the middle of health questions, tempting as that may be. However, we have been working with the Treasury, and also with the Academy of Medical Royal Colleges, the British Medical Association, employers in the NHS and others, to deliver on our manifesto commitment to sort this out.